CurrentUnitedHealthcarePolicy 2025 P 2236-3

Pa Med Nec Doxepin Cream Prudoxin Zonalon

Defines UnitedHealthcare prior authorization/medical necessity criteria for topical doxepin creams (Prudoxin, Zonalon) for short-term management of moderate pruritus in adults with atopic dermatitis or lichen simplex chronicus, including required prior treatment failures and authorization duration.

Policy Summary

PayerUnitedHealthcare

PolicyPa Med Nec Doxepin Cream Prudoxin Zonalon

Policy CodePolicy 2025 P 2236-3

Change TypeAnnual review — no changes

Effective DateJul 1, 2025

Next Review Date

Key ActionPrudoxin or Zonalon require prior authorization/medical necessity approval per the specified criteria prior to coverage; authorization will be issued for 1 month.

SourceLink

POLICY UPDATE CHANGES

Annual review with no changes documented on 4/2025.

2Covered Indications (AD, Lichen simplex chronicus)

8Max short-term duration (days)

1Authorization duration (months)

Coverage Summary

Defines UnitedHealthcare prior authorization/medical necessity criteria for topical doxepin creams (Prudoxin, Zonalon) for short-term management of moderate pruritus in adults with atopic dermatitis or lichen simplex chronicus. Coverage stance: covered_with_criteria. Initial approval requires documented diagnosis of moderate pruritus plus prior failure, contraindication, or intolerance to specified topical therapies (one topical corticosteroid and one topical calcineurin inhibitor for atopic dermatitis pathway, or a topical corticosteroid for lichen simplex chronicus pathway). Authorization will be issued for 1 month. Brand Prudoxin and Zonalon are typically excluded (generic preference implied); state mandates or member-specific benefit plans may override (see provider actions for details).

Initial Therapy Criteria (Prudoxin or Zonalon)

Initial Authorization - Prudoxin or Zonalon

Approved when ONE of the following criterion sets (A.a OR A.b) is fully met:

ALL of the following

Diagnosis of moderate pruritus due to atopic dermatitis
ONE of
- Failure, contraindication, or intolerance to one topical corticosteroid
  e.g., mometasone furoate, fluocinolone acetonide (generic Synalar), fluocinonide
- Failure, contraindication, or intolerance to one topical calcineurin inhibitor
  e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)

Alternative indication

Diagnosis of moderate pruritus due to lichen simplex chronicus
History of failure, contraindication, or intolerance to a topical corticosteroid
e.g., mometasone furoate, fluocinolone acetonide (generic Synalar), fluocinonide

Operational notes: Authorization is for short-term use (up to 8 days) and will be issued for 1 month.

Provider must document prior therapy failure/contraindication/intolerance; brand products typically excluded; state/federal mandates and member benefit may apply.

Continuation Therapy Criteria

There are no explicit continuation-therapy criteria in the clinical criteria sets; operationally, authorizations are issued for 1 month and the clinical indication is for short-term use (up to 8 days). Continued use beyond the indicated short-term duration or use without required documentation of prior therapy failure/contraindication/intolerance risks denial.

Exclusions / Limitations

Not covered / Excluded when

Use beyond indicated duration (greater than 8 days) or for indications other than moderate pruritus in atopic dermatitis or lichen simplex chronicus
Indication is short-term (up to 8 days); use outside indicated duration/indication risks denial.
Lack of documented failure, contraindication, or intolerance to the required prior topical corticosteroid or topical calcineurin inhibitor when such prior therapy is required by the criteria
Provider must document history of failure, contraindication, or intolerance to specified topical therapies; absence may lead to denial.

Additional exclusions/limits

Brand Prudoxin and Zonalon are typically excluded from coverage (generic preference).
State mandates and member-specific benefits may override.
Other program limits or supply limits may apply; lack of required documentation or non-covered program logic may result in denial.
Automated approvals may vary; other policies may apply.

Brand Prudoxin and Zonalon are typically excluded from coverage (a generic-preference is implied). Exceptions may apply per state mandates or member-specific benefit plans which can override the typical brand exclusion.

Provider Actions

Prior Authorization

Prior authorization required

Prudoxin or Zonalon require prior authorization/medical necessity approval per the specified criteria prior to coverage; authorization will be issued for 1 month.

Documentation Required

Document prior therapy failure/intolerance

Provider must document history of failure, contraindication, or intolerance to the specified topical corticosteroid or topical calcineurin inhibitor as applicable.

Billing Rule

Brand exclusions

Brand Prudoxin and Zonalon are typically excluded from coverage (generic preference implied); state mandates and member-specific benefit plans may override.

Denial Risk

Coverage limited to short-term use

Indication is for short-term use (up to 8 days); use outside indicated duration/indication or without required prior therapy documentation risks denial.

Clinical Evidence & Sources

Evidence and reference points include P&T approval/review dates: 4/2021, 3/2024, and 4/2025. Package inserts referenced: Prudoxin and Zonalon package inserts (June 2017). Clinical context: doxepin may provide a short-term decrease in pruritus but does not significantly reduce disease severity; AAD guidance prioritizes topical corticosteroids and topical calcineurin inhibitors before other agents. The policy uses the term "Moderate pruritus" as the clinical indication for topical doxepin therapy.

Background

Prudoxin and Zonalon (doxepin cream) are indicated for the short-term (up to 8 days) management of moderate pruritus in adults with atopic dermatitis or lichen simplex chronicus. Clinically, doxepin may reduce pruritus in the short term but does not significantly reduce overall disease severity or control. The American Academy of Dermatology recommends topical corticosteroids for atopic dermatitis patients who fail standard nonpharmacologic therapy and recommends topical calcineurin inhibitors for patients who fail or are not candidates for topical corticosteroids; these agents are prioritized before consideration of topical doxepin.